- Price
- $18.53
- Day
- +2.66%
- Mkt Cap
- $209.28M
- 52W Range
- $7.87 – $24.27
- Volume
- 1.15M
- Beta
- 0.79
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
WAYNE, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that Dr. Garry Neil, Chief Executive Officer of Avalo, will participate in the “Honing in on Hidradenitis” panel at the virtual BTIG Biotechnology Conference on Wednesday, July 29, 2026, at 10:30 am ET. Management will also host one-on-one investor meetings during the conference.
Read full article